Susquehanna Fundamental Investments, LLC Novo Cure LTD Transaction History

Susquehanna Fundamental Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	SELL	$56.44 - $118.81 $2.62 Million - $5.51 Million	-46,401 Reduced 88.78%	5,865 $352,000
Q4 2022 Feb 14, 2023	BUY	$63.98 - $85.37 $483,752 - $645,482	7,561 Added 16.91%	52,266 $3.83 Million
Q3 2022 Nov 14, 2022	SELL	$67.99 - $89.57 $2.48 Million - $3.26 Million	-36,446 Reduced 44.91%	44,705 $3.4 Million
Q1 2022 May 16, 2022	BUY	$60.15 - $84.52 $2.46 Million - $3.45 Million	40,869 Added 101.46%	81,151 $6.72 Million
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $497,329 - $808,061	6,624 Added 19.68%	40,282 $3.02 Million
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $2.5 Million - $4.19 Million	21,513 Added 177.13%	33,658 $3.91 Million
Q2 2021 Aug 11, 2021	BUY	$130.4 - $225.58 $1.58 Million - $2.74 Million	12,145 New	12,145 $2.69 Million

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.88B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.